<DOC>
	<DOC>NCT02817425</DOC>
	<brief_summary>This study is designed to compare the three chemotherapy regimens(TEGAFOX Sequential S-1 or SOX Sequential S-1 or SOX non-Sequential S-1) for postoperative patients with gastric cancer, observe and record the efficacy and tolerance,to evaluate which regimen is better.</brief_summary>
	<brief_title>A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>75≧Age≧18 Histologically or cytologically confirmed gastrointestinal cancer Stage Ⅱ or Ⅲ or Ⅳ ECOG ≦2 Accept the gastric cancer radical resection Life expectancy of at least three months Written informed consent to participate in the trial History of severe hypersensitivity reactions to the ingredients of S1\TF\5FU/calcium folinate or oxaliplatin Inadequate hematopoietic function which is defined as below: white blood cell (WBC) less than 5x10^9/L absolute neutrophil count (ANC) less than 2x10^9/L platelets less than 100*10^9/L Inadequate hepatic or renal function which is defined as below: serum bilirubin greater than 2 times the upper limit of normal range alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULN if no demonstrable liver metastases or greater than 5 times the ULN in the presence of liver metastases blood creatinine level greater than 2 times ULN Presence of peripheral neuropathy Receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine drug Women who is pregnant or lactating or fertile women of childbearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period (Including male) Psychiatric disorder or symptom that makes participation of the patient difficult; Concomitant illness that might be aggregated by active, noncontrolled disease such as congestive heart failure, ischemic heart disease, uncontrolled hypertension or arrhythmia with in six months Severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure, poorlycontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>S-1</keyword>
	<keyword>Adjuvant Chemotherapy</keyword>
	<keyword>TEGAFOX</keyword>
</DOC>